Comparing PolyPid (NASDAQ:PYPD) & BeOne Medicines (NASDAQ:ONC)

BeOne Medicines (NASDAQ:ONC) and PolyPid (NASDAQ:PYPD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk.

Profitability

This table compares BeOne Medicines and PolyPid’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	5.37%	10.70%	6.03%
PolyPid	N/A	-291.42%	-131.82%

Earnings & Valuation

This table compares BeOne Medicines and PolyPid”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34 billion	6.37	$286.93 million	$2.52	123.02
PolyPid	N/A	N/A	-$34.17 million	($2.26)	-1.96

BeOne Medicines has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for BeOne Medicines and PolyPid, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1	2	11	0	2.71
PolyPid	1	0	5	0	2.67

BeOne Medicines presently has a consensus target price of $385.08, suggesting a potential upside of 24.22%. PolyPid has a consensus target price of $12.25, suggesting a potential upside of 177.15%. Given PolyPid’s higher possible upside, analysts plainly believe PolyPid is more favorable than BeOne Medicines.

Volatility & Risk

BeOne Medicines has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, PolyPid has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.

Insider & Institutional Ownership

48.5% of BeOne Medicines shares are owned by institutional investors. Comparatively, 26.5% of PolyPid shares are owned by institutional investors. 6.6% of BeOne Medicines shares are owned by company insiders. Comparatively, 24.7% of PolyPid shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

BeOne Medicines beats PolyPid on 10 of the 13 factors compared between the two stocks.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.